Ferrer is committed to improving diagnosis and developing treatments for allergies, which are among the fastest growing pathologies in the world today.
Through the biopharmaceutical company Diater, we boast an extensive portfolio of products to improve the quality of life of patients affected by these sometimes life-threatening and debilitating diseases.
Founded in 1999, Diater is a market leader in providing medical professionals with the tools to respond to any medical need in the field of allergen immunotherapy and to personalize treatment to each patient.
Diater's products are the result of an in-depth knowledge of the allergen extracts used and a rigorous manufacturing process. And our vocation to innovate and develop means that there is a constant flow of new products to enhance medical practice and to contribute to the wellbeing of those affected by allergies.
Vaccines for the treatment of respiratory illnesses with an allergic origin are designed for allergen specific immunotherapy, in which the patient is administered with increasingly larger doses of the allergen, the substance that causes the allergic reaction.
According to the World Health Organization, the treatment of allergies using immunotherapy vaccines has been established as “the only treatment that may affect the natural course of allergic diseases, and it also may prevent the development of asthma in patients with allergic rhinitis”.
Immunotherapy, therefore, helps improve the life of patients with allergies, offering a long-term preventative effect which improves clinical and immunological intolerance. In Ferrer, we believe in treatments that address the cause and origin of the problem. Treatments that can change lives.
Diater is a pharmaceutical laboratory specialised in allergies, committed to providing a full range of diagnostic and immunotherapy products to specialized physicians in order to facilitate their practice and improve the patient's quality of life.